BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors

Abstract Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in the development of immunogenicity. The objective of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Borja Hernández-Breijo, Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, Ioannis Parodis, Johanna E. Gehin, Ana Martínez-Feito, Marta Novella-Navarro, Araceli Mezcua, David J. Warren, Pilar Nozal, Dora Pascual-Salcedo, Alejandro Balsa
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/23161f74c66b452fadeaadcaeff92d76
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:23161f74c66b452fadeaadcaeff92d76
record_format	dspace
spelling	oai:doaj.org-article:23161f74c66b452fadeaadcaeff92d762021-12-02T17:51:06ZBAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors10.1038/s41598-021-91177-42045-2322https://doaj.org/article/23161f74c66b452fadeaadcaeff92d762021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91177-4https://doaj.org/toc/2045-2322Abstract Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in the development of immunogenicity. The objective of this study was to analyse the association of baseline concentration of serum B-cell activating factor (BAFF) with immunogenicity after 6 months of TNFi treatment. A total of 127 patients with RA starting a TNFi (infliximab, adalimumab, certolizumab pegol or golimumab) were followed-up for 6 months. Serum samples were obtained at baseline and at 6 months and anti-drug antibody (ADA) and BAFF concentrations were measured. Logistic regression models were employed in order to analyse the association between BAFF concentrations and immunogenicity. Receiver operating characteristic analysis was performed to determine the BAFF concentrations with a greater likelihood of showing immunogenicity association. At 6 months, 31 patients (24%) developed ADA. A significant interaction between the age and baseline BAFF concentration was found for the development of ADA (Wald chi-square value = 5.30; p = 0.02); therefore, subsequent results were stratified according to mean age (≤ / > 55 years). Baseline serum BAFF concentration was independently associated with ADA development only in patients over 55 years (OR = 1.51; 95% CI 1.03–2.21). Baseline serum BAFF ≥ 1034 pg/mL predicted the presence of ADA at 6 months (AUC = 0.81; 95% confidence interval (CI) 0.69–0.93; p = 0.001; positive likelihood ratio = 3.7). In conclusion, our results suggest that the association of BAFF concentration and immunogenicity depends on the patient’s age. Baseline serum BAFF concentration predicts the presence of ADA within 6 months of TNFi therapy in older patients with RA.Borja Hernández-BreijoVictoria Navarro-CompánChamaida Plasencia-RodríguezIoannis ParodisJohanna E. GehinAna Martínez-FeitoMarta Novella-NavarroAraceli MezcuaDavid J. WarrenPilar NozalDora Pascual-SalcedoAlejandro BalsaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Borja Hernández-Breijo Victoria Navarro-Compán Chamaida Plasencia-Rodríguez Ioannis Parodis Johanna E. Gehin Ana Martínez-Feito Marta Novella-Navarro Araceli Mezcua David J. Warren Pilar Nozal Dora Pascual-Salcedo Alejandro Balsa BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
description	Abstract Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in the development of immunogenicity. The objective of this study was to analyse the association of baseline concentration of serum B-cell activating factor (BAFF) with immunogenicity after 6 months of TNFi treatment. A total of 127 patients with RA starting a TNFi (infliximab, adalimumab, certolizumab pegol or golimumab) were followed-up for 6 months. Serum samples were obtained at baseline and at 6 months and anti-drug antibody (ADA) and BAFF concentrations were measured. Logistic regression models were employed in order to analyse the association between BAFF concentrations and immunogenicity. Receiver operating characteristic analysis was performed to determine the BAFF concentrations with a greater likelihood of showing immunogenicity association. At 6 months, 31 patients (24%) developed ADA. A significant interaction between the age and baseline BAFF concentration was found for the development of ADA (Wald chi-square value = 5.30; p = 0.02); therefore, subsequent results were stratified according to mean age (≤ / > 55 years). Baseline serum BAFF concentration was independently associated with ADA development only in patients over 55 years (OR = 1.51; 95% CI 1.03–2.21). Baseline serum BAFF ≥ 1034 pg/mL predicted the presence of ADA at 6 months (AUC = 0.81; 95% confidence interval (CI) 0.69–0.93; p = 0.001; positive likelihood ratio = 3.7). In conclusion, our results suggest that the association of BAFF concentration and immunogenicity depends on the patient’s age. Baseline serum BAFF concentration predicts the presence of ADA within 6 months of TNFi therapy in older patients with RA.
format	article
author	Borja Hernández-Breijo Victoria Navarro-Compán Chamaida Plasencia-Rodríguez Ioannis Parodis Johanna E. Gehin Ana Martínez-Feito Marta Novella-Navarro Araceli Mezcua David J. Warren Pilar Nozal Dora Pascual-Salcedo Alejandro Balsa
author_facet	Borja Hernández-Breijo Victoria Navarro-Compán Chamaida Plasencia-Rodríguez Ioannis Parodis Johanna E. Gehin Ana Martínez-Feito Marta Novella-Navarro Araceli Mezcua David J. Warren Pilar Nozal Dora Pascual-Salcedo Alejandro Balsa
author_sort	Borja Hernández-Breijo
title	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
title_short	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
title_full	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
title_fullStr	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
title_full_unstemmed	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
title_sort	baff predicts immunogenicity in older patients with rheumatoid arthritis treated with tnf inhibitors
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/23161f74c66b452fadeaadcaeff92d76
work_keys_str_mv	AT borjahernandezbreijo baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT victorianavarrocompan baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT chamaidaplasenciarodriguez baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT ioannisparodis baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT johannaegehin baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT anamartinezfeito baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT martanovellanavarro baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT aracelimezcua baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT davidjwarren baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT pilarnozal baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT dorapascualsalcedo baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors AT alejandrobalsa baffpredictsimmunogenicityinolderpatientswithrheumatoidarthritistreatedwithtnfinhibitors
_version_	1718379273599844352

BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors

Ejemplares similares